Hui-Fang Chang is a prominent inventor based in Wilmington, Delaware, known for her significant contributions to pharmaceutical chemistry. With a total of seven patents to her name, she has made remarkable advancements in the field of nicotinic acetylcholine receptor ligands.

Latest Patents

Her latest patents include innovative compounds such as nicotinic acetylcholine receptor ligands of Formula I, which encompass diastereoisomers, enantiomers, and pharmaceutically-acceptable salts. These compounds are detailed in her specifications, along with methods of making and pharmaceutical compositions containing them. Another notable patent involves oxazolidinone nicotinic acetylcholine receptor agonists, which are defined by specific formulas and include pharmaceutical compositions and formulations. These inventions aim to treat various diseases and conditions, either alone or in combination with other therapeutically-active compounds.

Career Highlights

Hui-Fang Chang is currently employed at AstraZeneca AB, where she continues to push the boundaries of pharmaceutical research. Her work has been instrumental in developing new therapeutic options for patients.

Collaborations

Some of her notable coworkers include Eifion D. Phillips and Marc Chapdelaine, who contribute to her innovative projects and research endeavors.

Conclusion

Hui-Fang Chang's work exemplifies the spirit of innovation in pharmaceutical chemistry, and her patents reflect her dedication to improving healthcare through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.